Exosomes from Hypoxic Tumors - Mediators of Cancer Metastasis
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.
Oncotarget 2016 Jun 07;7(23):34907-17.
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.
BMC Cancer 2016 Jul 26;16():536. Epub 2016 jul 26
Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
BMC Cancer 2016 Jul 26;16():531. Epub 2016 jul 26
Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor K(trans) and ?R2* peak are significantly associated with lymph node metastasis.
J Magn Reson Imaging 2016 Dec 21. Epub 2016 des 21
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.
Int J Mol Sci 2014;15(12):22835-56. Epub 2014 des 9
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.
J Enzyme Inhib Med Chem 2014 Oct 27. Epub 2014 okt 27